ストックスクリーナーアプリを入手
14.39
1.77%
-0.26
前日終値:
$14.65
開ける：
$14.34
24時間の取引高:
619.44K
Relative Volume:
0.50
時価総額：
$1.21B
収益：
-
当期純損益:
$-44.17M
株価収益率:
-27.36
EPS:
-0.526
ネットキャッシュフロー:
$-35.14M
1週間 パフォーマンス:
+1.62%
1か月 パフォーマンス:
+3.38%
6か月 パフォーマンス:
-19.34%
1年 パフォーマンス:
+151.13%
1日の値動き範囲:
$14.34
$14.74
1週間の範囲:
$13.71
$14.82
52週間の値動き範囲:
$5.64
$26.95
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
名前
Corvus Pharmaceuticals Inc
セクター
電話
(650) 900-4520
住所
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA
Compare CRVS vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
14.39 | 1.21B | 0 | -44.17M | -35.14M | -0.526 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | Goldman | Buy |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-01-02 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-18 | 開始されました | Oppenheimer | Outperform |
| 2021-12-01 | 再開されました | Jefferies | Buy |
| 2021-05-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-10 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-09-12 | 開始されました | Mizuho | Buy |
| 2019-05-29 | 開始されました | ROTH Capital | Buy |
| 2017-08-24 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2017-05-01 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2016-04-18 | 開始されました | Credit Suisse | Outperform |
| 2016-04-18 | 開始されました | Guggenheim | Buy |
すべてを表示
Corvus Pharmaceuticals Inc (CRVS) 最新ニュース
Blue Owl Capital Holdings LP Takes Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Will Corvus’ Sharply Wider 2026 Losses Recast Its Risk‑Reward Profile for Investors (CRVS)? - simplywall.st
637,500 Shares in Corvus Pharmaceuticals, Inc. $CRVS Bought by DCF Advisers LLC - MarketBeat
Corvus (CRVS) Q2 2026 Results: The EPS Result Is Below Expectation; Market Response: The Stock Records a 3.84% Increase in the Current UpdateFinancial Health Score - Vinanet
Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting - Yahoo Finance
Corvus Pharmaceuticals (CRVS) Reports A Wider Loss, Is The Stock Still Cheap? - Sahm
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside - Stocktwits
Corvus Pharmaceuticals Stock Price Forecast. Should You Buy CRVS? - StockInvest.us
Renaissance Technologies LLC Takes $1.19 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value (NASDAQ:CRVS) - Seeking Alpha
HC Wainwright Issues Negative Estimate for CRVS Earnings - MarketBeat
Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
HC Wainwright Brokers Decrease Earnings Estimates for CRVS - MarketBeat
The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
H.C. Wainwright Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $27 - Moomoo
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement - Seeking Alpha
Is Corvus Pharmaceuticals (CRVS) Undervalued After A Wider Q2 Loss? - Sahm
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corvus Pharmaceuticals (CRVS) Gets a Buy from Oppenheimer - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Posts Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Corvus Pharmaceuticals Loss Widens to $18 Million as Soquelitinib Trial Costs Soar - finance.biggo.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Down After Earnings Miss - MarketBeat
State Street Corporation (NYSE: STT) discloses 5.3% ownership in Corvus Pharmaceuticals - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRVS SWOT Analysis: Financial Losses and Growth Potential Revealed in 10-Q Filing - GuruFocus
Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... - Yahoo Finance
Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Corvus Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Corvus posts wider Q2 2026 loss as trials advance - Investing.com
Corvus Eczema Trial Is Expected to Enroll About 200 Patients - stocktitan.net
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corvus Pharmaceuticals 2Q 2026: Net income $(17.96)M, EPS $(0.19) — 10-Q Summary - TradingView
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Corvus Pharmaceuticals earnings up next as trial progress eyed By Investing.com - Investing.com Nigeria
8-K: Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Resultsmoomoo - Moomoo
82,890 Shares in Corvus Pharmaceuticals, Inc. $CRVS Acquired by Seven Fleet Capital Management LP - MarketBeat
Avidity Partners Management LP Invests $1.68 Million in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Vivo Capital LLC Has $41.05 Million Position in Corvus Pharmaceuticals, Inc. $CRVS - MarketBeat
Corvus Pharmaceuticals' Q2 Business Update Will Stream Live Aug. 6 - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Corvus Pharmaceuticals Inc (CRVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BlackRock (CRVS holder) reports 7.5% beneficial stake in Corvus Pharmaceuticals - Stock Titan
Corvus Pharmaceuticals Inc (CRVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:12.925|Chg%:-0.145 - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corvus Pharmaceuticals Inc (CRVS) Institutional Confidence - TradingKey
CRVS|Corvus Pharmaceuticals Inc|Price:13.070|Chg%:-0.610 - TradingKey
Corvus Pharmaceuticals Inc (CRVS) 財務データ
収益
当期純利益
現金流量
EPS
Corvus Pharmaceuticals Inc (CRVS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MILLER RICHARD A MD | President and CEO |
May 18 '26 |
Buy |
12.04 |
6,932 |
83,453 |
1,195,035 |
| Thompson Peter A. | Director |
Jan 28 '26 |
Option Exercise |
5.33 |
210,000 |
1,119,374 |
210,000 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):